A four-year-old London startup backed by Peter Thiel has raised a $55 million Series B round as it sets about “fixing the broken clinical trial industry.” The announcement comes as artificial intelligence is shaping up to revolutionize drug discovery and development, in turn spurring demand for a streamlined clinical trial process to help get new…
IT & Security News for Geeks